The sale netted about $300 million for Walgreens and shrinks the company’s stake in Cencora to approximately 6%, down from 10 ...

Cencora has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance’s sale ...

Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said ...

Cencora Inc’s (NYSE:COR), formerly AmerisourceBergen Corporation, first quarter 2024 adjusted EPS reached $3.28, up from $2.71 Y/Y, beating the consensus of $2.89. In the first quarter ...

Drug distributor Cencora raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines.

Cencora, a global healthcare company, has expanded its Sure Supply Program to include 200 critical medications, including several oncology treatments, in response to ongoing drug shortages.

Cencora is now targeting an 8% to 10% rise in revenue for the full fiscal year, a lift from its previous guidance for 7% to 9% growth. Sales are expected to rise 9% to 11% in its U.S. healthcare ...

$60,000 of CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. In yet another move to pay down debt that matures in ...

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments.